Abstract Details

Title Gut microbiota composition in untreated people with relapsing-remitting and secondary-progressive Multiple Sclerosis

Topic Multiple Sclerosis

Presentation(s) P2 - Poster Session 2 (11:45 AM-12:45 PM)

Poster/Presentation
Number 3-008

Objective

To investigate prospectively the qualitative&quantitative differences in the faecal bacterial composition of untreated patients with RRMS and SPMS.

Background Alterations in gut microbiome composition are suggested to act as a driver in the transition of RRMS to secondary-progressive MS (SPMS).

Design/Methods We present prospective 16S rRNA gene high-throughput sequencing data from faecal samples of 33 patients with RRMS and 10 patients with SPMS. Differences between gut microbiota composition were validated prospectively at three time-points over 12-months. We used available microbial profiles of healthy controls and RRMS from a different population (Jangi-et-al.2016) for comparative analyses with our own data. We studied blood T regulatory cell (CD4+CD25highFoxp3+) associations with specific gut bacterial taxa.

Results While some gut microbiota composition traits were common to RRMS and SPMS patients, we identified a small number of distinctive bacteria associated with SPMS; of these, the genus Slackia. Slackia exigua is known to be part of gut dysbiosis associated with cancer progression. There were no significant correlations between Treg counts and abundance of selected bacterial taxa significantly associated with RRMS or SPMS.

Conclusions Subtle differences were observed between the gut bacterial composition of SPMS patients and that of RRMS.

Authors/Disclosures
Radu Tanasescu, MD, PhD, FAAN (Clinical Neurology) PRESENTER	Dr. Tanasescu has received personal compensation for serving as an employee of Merck. Dr. Tanasescu has received personal compensation for serving as an employee of Novartis. Dr. Tanasescu has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Tanasescu has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Dr. Tanasescu has received research support from UK MRC grant MR/T024402/1.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Cris S. Constantinescu, MD, PhD (Cooper Neurological Institute)	Dr. Constantinescu has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��